Constitutive and treatment-induced CXCL8-signalling selectively modulates the efficacy of anti-metabolite therapeutics in metastatic prostate cancer

PLoS ONE

Volumn 7, Issue 5, 2012, Pages

  Wilson, Catherine ^a   Maxwell, Pamela J ^a   Longley, Daniel B ^a   Wilson, Richard H ^a   Johnston, Patrick G ^a   Waugh, David J J ^a  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE RECEPTOR CXCR1; CHEMOKINE RECEPTOR CXCR2; FLUOROURACIL; INTERLEUKIN 8; PEMETREXED; RALTITREXED; SMALL INTERFERING RNA; THYMIDYLATE SYNTHASE; ANTINEOPLASTIC ANTIMETABOLITE; IL8 PROTEIN, HUMAN; TUMOR PROTEIN;

APOPTOSIS; ARTICLE; CANCER CELL; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG MECHANISM; DRUG RESPONSE; DRUG SENSITIVITY; GENE EXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; MALE; PROSTATE CANCER; PROTEIN EXPRESSION; PROTO ONCOGENE; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; DRUG ANTAGONISM; DRUG EFFECT; GENETICS; METABOLISM; METASTASIS; PATHOLOGY; PROSTATE TUMOR; TUMOR CELL LINE;

ANTIMETABOLITES, ANTINEOPLASTIC; CELL LINE, TUMOR; HUMANS; INTERLEUKIN-8; MALE; NEOPLASM METASTASIS; NEOPLASM PROTEINS; PROSTATIC NEOPLASMS; RECEPTORS, INTERLEUKIN-8A; RECEPTORS, INTERLEUKIN-8B; SIGNAL TRANSDUCTION;

EID: 84860745316     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0036545     Document Type: Article

References (25)

1. Attard G, Reid AH, de Bono JS, (2010) Abiraterone acetate is well tolerated without the concomitant use of corticosteroids. J Clin Oncol 28: e560-1.
2. de Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, et al. (2011) Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 364: 1995-2005.
3. Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, et al. (2004) Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351: 1502-12.
4. Longley DB, Harkin DP, Johnston PG, (2003) 5-fluorouracil: mechanisms of action and clinical strategies. Nature Rev Cancer 3: 330-338.
5. Vaishampayan UN, Marur S, Heilbrun LK, Cher ML, Dickow B, et al. (2009) Phase II trial of capecitabine in combination with weekly docetaxel for metastatic castrate resistant prostate cancer. J Urol 182: 317-23.
6. Gasent Blesa JM, Giner Marco V, Giner-Bosch V, Cerezuela Fuentes P, Alberola Candel V, (2011) Phase II trial of oxaliplatin and capecitabine after progression to first-line chemotherapy in androgen-independent prostate cancer patients. Am J Clin Oncol 34: 155-159.
7. Murphy C, McGurk M, Pettigrew J, Santinelli A, Mazzucchelli R, et al. (2005) Nonapical and cytoplasmic expression of interleukin-8, CXCR1 and CXCR2 correlates with cell proliferation and microvessel density in prostate cancer. Clin Cancer Res 11: 4117-412.
8. Uehara H, Troncoso P, Johnston D, Bucana CD, Dinney C, et al. (2005) Expression of interleukin-8 gene in radical prostatectomy specimens is associated with advanced pathologic stage. Prostate 64: 40-9.
9. Maxwell PJ, Gallagher R, Seaton A, Wilson C, Scullin P, et al. (2007) HIF-1 and NF-kappaB-mediated upregulation of CXCR1 and CXCR2 expression promotes survival in hypoxic prostate cancer cells. Oncogene 26: 7333-45.
10. Wilson C, Purcell C, Seaton A, Oladipo O, Maxwell PJ, et al. (2008a) Chemotherapy-induced CXC-chemokine/CXC-chemokine receptor signalling in metastatic prostate cancer cells confers resistance to oxaliplatin through potentiation of nuclear factor-kappaB transcription and evasion of apoptosis. J Pharm Exp Ther 327: 746-759.
11. Wilson C, Wilson T, Johnston PG, Longley DB, Waugh DJ, (2008b) Interleukin-8 signaling attenuates TRAIL- and chemotherapy-induced apoptosis through transcriptional regulation of c-FLIP in prostate cancer cells. Mol Cancer Ther 7: 2649-2661.
12. Araki S, Omori Y, Lyn D, Singh RK, Meinbach DM, et al. (2007) Interleukin-8 is a molecular determinant of androgen-independence and progression in prostate cancer. Cancer Res 67: 6854-6862.
13. Seaton A, Scullin P, Maxwell PJ, Wilson C, Pettigrew J, et al. (2008) Interleukin-8 signaling promotes androgen-independent proliferation of prostate cancer cells via induction of androgen receptor expression and activation. Carcinogenesis. 29: 1148-1156.
14. MacManus CF, Pettigrew J, Seaton A, Wilson C, Maxwell PJ, et al. (2007) Interleukin-8 signaling promotes translational regulation of cyclin D1 in androgen-independent prostate cancer cells. Mol Cancer Res 5: 737-748.
15. Seaton A, Maxwell PJ, Hill A, Gallagher R, Pettigrew J, et al. (2009) Inhibition of constitutive and CXC-chemokine-induced NF-kappaB activity potentiates ansamycin-based Hsp90-inhibitor cytotoxicity in castrate-resistant prostate cancer cells. Br J Cancer 101: 1620-1629.
16. Kaighn ME, Narayan KS, Ohnuki Y, Lechner JF, Jones LW, (1979) Establishment and characterization of a human prostate adenocarcinoma cell line (PC-3). Invest Urol 17: 16-23.
17. Adjei AA, (2004) Pemetrexed (ALIMTA): a novel multitargeted antineoplastic agent. Clin Cancer Res 10: 4276s-4280s.
18. Johnston PG, Lenz HJ, Leichman CG, Danenberg KD, Allegra CJ, et al. (1995) Thymidylate synthase gene and protein expression correlate and are associated with response to 5-fluorouracil in human colorectal and gastric tumors. Cancer Res 55: 1407-12.
19. Salonga D, Danenberg KD, Johnson M, Metzger R, Groshen S, et al. (2000) Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase. Clin Cancer Res 6: 1322-7.
20. Veltri RW, Miller MC, Partin AW, Poole EC, O'Dowd GJ, (1999) Interleukin-8 serum levels in patients with benign prostatic hyperplasia and prostate cancer. Cancer 91: 2322-2328.
21. Hahn NM, Zon RT, Yu M, Ademuyiwa FO, Jones T, et al. (2009) A phase II study of pemetrexed as second-line chemotherapy for the treatment of metastatic castrate-resistant prostate cancer (CRPC)- Hoosier Oncology Group GU03-67. Ann Oncol 20: 1971-1976.
22. Caffo O, Fratino L, Barbieri R, Perin A, Martini T, et al. (2011) Pemetrexed as second-line chemotherapy for castrate-resistant prostate cancer after docetaxel failure: results from a phase II study. Urol Oncol, epub ahead of print Jul 29.
23. Bendre MS, Gaddy-Kurten D, Mon-Foote T, Akel NS, Skinner RA, et al. (2002) Expression of interleukin 8 and not parathyroid hormone-related protein by human breast cancer cells correlates with bone metastasis in vivo. Cancer Res. 62: 5571-5579.
24. Ning Y, Manegold PC, Hong YK, Zhang W, Pohl A, et al. (2011) Interleukin-8 is associated with proliferation, migration, angiogenesis and chemosensitivity. Int J Cancer 128: 2038-49.
25. Droz JP, Muracciole X, Mottet N, Ould Kaci M, Vannetzel JM, et al. (2003) Phase II study of oxaliplatin versus oxaliplatin combined with infusional 5-fluorouracil in hormone refractory metastatic prostate cancer patients. Ann Oncol 14: 1291-8.